Treczimus 0.03% ointment 20 grams

Tradename

Treximus

Treczimus

Composition

Each gram of ointment contains:

Tacrolimus 0.03 mg

Properties

Tacrolimus belongs to the group of calcineurin inhibitors. It binds to a specific cytoplasmic protein immunophilin (FKBP12), which is the cytosolic receptor for calcineurin (FK506). As a result, a complex is formed that includes tacrolimus, FKBPI2, calcium, calmodulin and calcineurin, which leads to inhibition of the phosphatase activity of calcineurin. This makes it impossible for dephosphorylation and translocation of the nuclear factor of activated T cells (NFAT), which is necessary for the initiation of transcription of genes encoding the production of cytokines, key for the T-cell immune response (IL-2 and interferon-gamma). In addition, tacrolimus inhibits the transcription of genes encoding the production of cytokines such as IL-3, IL-4, IL-5, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor (TNFα), which are involved in the initial stages of T activation. — lymphocytes. In addition, under the influence of tacrolimus, the release of inflammatory mediators from mast cells, basophils and eosinophils is inhibited, as well as a decrease in the expression of FcεRI (high-affinity surface receptor for immunoglobulin E) on Langerhans cells, which leads to a decrease in their activity and antigen presentation to T-lymphocytes. tacrolimus does not affect collagen synthesis and thus does not cause skin atrophy.

Indications

treatment of atopic dermatitis (of moderate severity and severe forms) in case of its resistance to other means of external therapy or the presence of contraindications to such.

In adults and children over 2 years old, Treximus ointment is used in the form of 0.03% ointment.

Method of administration and dosage:

Contraindications

— serious violations of the epidermal barrier, in particular, Netherton’s syndrome, lamellar ichthyosis, skin manifestations of the graft versus host reaction, as well as generalized erythroderma (due to the risk of increased systemic absorption of tacrolimus);

-Children up to 2 years old (for 0.03% ointment);

— children and adolescents up to 16 years old (for 0.1% ointment);

Side effects

Infectious diseases: often — local skin infections, regardless of etiology (in particular, but not limited to those listed, Kaposi’s herpetic eczema, folliculitis, infection caused by the Herpes simplex virus, other infections caused by viruses of the Herpes viridae family).

From the side of metabolism and nutrition: often — alcohol intolerance (flushing of the face or symptoms of skin irritation after drinking alcohol).

From the nervous system: often — paresthesia, hyperesthesia.